Aims: To study the effect of adjunctive systemic administration of melatonin to standard mechanical periodontal therapy in obese rats with experimental periodontitis.
| INTRODUC TI ON
The association between periodontitis and obesity has been evidenced both in experimental (Perlstein & Bissada, 1977) and epidemiological studies (Keller, Rohde, Raymond, & Heitmann, 2015) .
In fact, overweight and obese subjects are more than twice more likely to suffer from periodontitis when compared to normalweight individuals (Suvan, D'Aiuto, Moles, Petrie, & Donos, 2011 (Suvan et al., 2011) .
These epidemiological associations between periodontitis and obesity have been explained by the sharing of common risk factors, since both are chronic inflammatory diseases leading to increased systemic inflammation, metabolic dysregulation and dyslipidemia . In spite of these common inflammatorymediated mechanisms, the specific underlying biological pathways linking both diseases remain partly unknown. Some authors have suggested the possible influence of alterations in the circadian cycle, since significant reductions in the melatonin hormone levels were reported in experimental studies in both, obesity and periodontitis (Shimizu, Yoshida, & Minamino, 2016; Virto, Haugen, et al., 2018) .
In fact, when melatonin was administered in obese subjects, significant reductions in systemic pro-inflammatory biomarkers together with reductions in body weight and adipose tissue deposits were reported (Favero et al., 2015; Rios-Lugo et al., 2010) . Similarly, adjunctive topical applications of melatonin to standard periodontal therapy have resulted in significant reductions in gingival inflammation (Arabacı et al., 2015; Cutando et al., 2014) .
Despite these reported beneficial effects, there is no evidence of the potential benefit of melatonin when used as adjunctive therapy in the treatment of periodontitis associated with obesity. It was, therefore, the main objective of this experimental in vivo investigation, to evaluate the efficacy of adjunctive systemic administration of melatonin to standard mechanical cause-related periodontal therapy, compared with the same mechanical debridement plus the gold standard antimicrobial agent, chlorhexidine (CHX).
| MATERIAL S AND ME THODS

| Animals and experimental design
This investigation was carried out in the Experimental Animal Center at the University Complutense of Madrid (UCM), Madrid, Spain and was conducted according to the Spanish and European Union regulations (European Communities Council Directive 86/609/EEC) following the ARRIVE guidelines (Kilkenny, Browne, Cuthill, Emerson, & Altman, 2010) . The Institutional UCM Animal Care Committee and the Regional Authorities approved the study protocol and the proposed animal care and welfare measures.
This pre-clinical in vivo investigation used 42 two-month-old Wistar rats with an initial body weight of 180 g. maintained during the study under standard housing conditions, with controlled light (12-hr light/12-hr dark schedule; lights on at 08:00 hours) and temperature (22°C ± 2°C). These animals were weighed once a week and any procedures involving any potential pain were made under anaesthesia using a combination of ketamine (0.08 ml/100 g) and xylazine (0.04 ml/100 g) under appropriate concentrations (Brandelero et al., 2012) .
| Induction of obesity and periodontitis
In half of the experimental animal population, obesity was induced by feeding the experimental animals ad libitum with a high-fat diet (HFD) (TD03307; Envigo, Castellar del Vallès, Barcelona, Spain) containing 35.2% fat, 35.5% carbohydrates, 20.4% protein, and 8.9% vitamins and minerals in 100 g of chow. Obesity was diagnosed when the rats using this HFD weighted 15% more than the rats fed with the standard diet (Envigo) containing 3% fat, 60% carbohydrates, 16% protein, and 21% vitamins and minerals in 100 g of chow. Obesity induction was usually achieved after 2 months with this HFD.
In both obese and normal-weight animals, experimental periodontitis was subsequently induced using a modification of the method described by Polak et al. (2009) 
Clinical Relevance
Scientific rationale for the study: The combination of periodontitis and obesity results in enhanced systemic inflammation and reduced circulating levels of melatonin. In this study, we have investigated the possible therapeutic effect of adjunctive systemic administration of melatonin in obese-periodontitis, when compared with normal-weight periodontitis experimental animals.
Principal findings:
The systemic administration of adjunctive melatonin significantly improved periodontal parameters reduced alveolar bone loss and corrected the systemic dysregulation associated mainly when periodontitis was combined with obesity.
Practical implications: These findings provide a new insight to the treatment of the association of periodontitis with obesity, since the adjunctive use of systemic melatonin not only improved periodontal outcomes but also reduced inflammation, vascular injury and lipid metabolism dysregulation.
at 37°C. Once a pre-established density (10 9 cells/ml, adjusted by spectrophotometry at 550 nm) was achieved, bacteria were separated from the culture media by centrifugation (10 min at 1,520 g), re-suspended in sterile 2% carboxymethyl cellulose (Sigma, St.
Louis, MO) and vortexed (in continuous mode for 1-2 min). One millilitre of this bacterial suspension was administered to the experimental animals through oral gavages for 4 consecutive days during 12 weeks without requiring anaesthesia . The bacterial culture growth phase, suspension media, infection doses and induction procedures were all standardized throughout the study.
| Experimental design
This investigation was designed as a parallel-arm in vivo experimental study using a randomized block, examiner blind design. The These groups were each randomly assigned to the following interventions:
• experimental treatment consisting on standard mechanical debridement plus adjunctive melatonin;
• control treatment consisting on standard mechanical debridement plus adjunctive CHX;
• The following outcome parameters were used to evaluate the clinical status of the periodontal tissues:
• Plaque accumulation (PII)
Mandibular first left molar was smeared with 2% basic fuchsine for 30 s and then washed. Stained purple surfaces were photographed (Liu et al., 2012) and then measured using a dedicated image software (Image Tool3) (Cavagni et al., 2013 ).
• Gingival index (MGI)
The Modified Gingival Index (MGI) by Lobene, Weatherford, Ross, Lamm, and Menaker (1986) (Lobene et al., 1986 ).
• Bleeding on probing (BOP)
Ten seconds after light periodontal probing of the first left molar.
"1" was assigned in the presence of bleeding a "0" in absence (Lang, Joss, Orsanic, Gusberti, & Siegrist, 1986 ).
• Probing pocket depth (PD)
Probing pocket depth was measured from the gingival margin to the bottom of the pocket using a round-ended periodontal probe with a tip of 0.4 mm in diameter (Hu-Friedy Mfg. o, LLC, Chicago) under light pressure. Previous studies in the same experimental animals have defined probing depths of ≤0.30 mm as gingival health (Liu et al., 2012) and periodontitis when probing depths were ≥0.5 mm (Björnsson et al., 2003; Simch, Gaio, & Rosing, 2008) . Gingival specimens were dissected from the upper jaws and immediately frozen at −80°C. These gingival specimens (10 mg) were homogenized using a high-speed benchtop homogenizer (FastPrep, 24 ™ 5G; MP Biomedicals, USA) in 1 ml of phosphate buffer with protease inhibitor and <2% triton. Pro-inflammatory cytokines IL-1 β, IL-6, TNF-α and MCP-1 were measured using a flow cytometry analyser as are described below.
Left hemi-mandibles were carefully removed and fixed in 4% formalin solution (Applichem Panreac; Barcelona, Spain). These specimens were studied by micro-computed tomography (micro-CT) using a high-resolution micro-CT system (Skyscan 1172; Bruker microCT, Kontich, Belgium) with a 4.96 μm voxel resolution and a source voltage of 100 kV and 100 μA plus an aluminium and copper filter of 0.5 mm to optimize the contrast. The resulting teeth were rotated 360° around their long axes and four absorption images were recorded every 0.400° of rotation. These raw images were then reconstructed through 3D cone-beam reconstruction algorithms using the standard SkyScan ® reconstruction software (NRecon 1.6.10; Bruker microCT) to coronally oriented serial tomograms. For these reconstructions, beam hardening was set to 25% and ring artefact reduction to 15. After the scanning, the teeth were aligned and measured in 3D with DataViewer (Bruker microCT). For evaluating the alveolar bone levels, the distance between the cemento-enamel junction and the alveolar bone crest [CEJ-AC] was measured five times at six different points (mesio-buccal, buccal, disto-buccal, disto-lingual, lingual and mesio-lingual) by an independent blinded experienced investigator.
| Statistical analysis
Data were expressed as means (SEM) and 95% confidence intervals (95% CI). For all evaluated parameters, the normality was tested by Notes. Data are expressed as means (SEM) in pg/ml. The column "difference" represents the magnitude of difference between non-treated control groups (NW-Perio and HFD-Perio) and treated groups.
IL-1β: interleukin-1β; IL-6: interleukin-6; MCP-1: Monocyte Chemoattractant Protein-1; TNF-α: Tumour necrosis factor alpha. *p < 0.05 statistically significant differences between change between non-treated control groups and treated groups. Notes. Data are expressed as means (SEM) in pg/ml. The column "difference" represents the magnitude of difference between non-treated control groups (NW-Perio and HFD-Perio) and treated groups.
TA B L E 5 Effect of the adjunctive treatments (CHX or MEL) on systemic inflammatory biomarkers
IL-1β: interleukin-1β; IL-6, interleukin-6; MCP-1; Monocyte Chemoattractant Protein-1; TNF-α: Tumour necrosis factor alpha. *p < 0.05 statistically significant differences between treatment groups (CHX or MEL) versus controls (C-Perio or HFD-Perio).
between groups. All analyses were performed in BM SPSS Statistics 22.0; (IBM Corporation, Armonk, NY, USA). The animal was the unit of analysis, and the alpha level was set at 0.05.
| RE SULTS
At week 24, both obesity and periodontitis were induced, with the HFD-Perio group resulting in a 58.7% increase in weight compared with the NW-Perio group. At the end of the treatment period (Week-29), in spite of the maintenance of high-fat diet, the adjunctive use of melatonin (HFD-Perio-Mel group) resulted in a significantly lesser body weight gain (12% less weight gain), when compared with the control treatment group (HFD-Perio CHX group). Table 1 Table 2 represents the effect of the tested interventions for the NW-Perio and HFD-Perio groups, on the clinical parameters between baseline (week-24) and post-therapy (weeks 26 and 29, respectively). In both animal groups, the interventions resulted in significant reductions in the levels of gingival inflammation and BOP.
In the HFD-Perio group, however, the adjunctive systemic administration of melatonin always achieved better clinical outcomes when compared to the adjunctive use of CHX, although statistically significant differences were only encountered for BOP reductions. Table 3 Notes. The column "difference" represents the magnitude of difference (follow by SEM) between non-treated control groups (NW-Perio and HFD-Perio) and treated groups. FFA: free fatty acids; HDL-C: high-density lipoprotein; LDL-C: low-density lipoprotein; OC: osteocalcin; OPN: osteopontin; PAI-1: plasminogen activator inhibitor-1; TG: triglycerides;TC: total cholesterol. *p < 0.05 statistically significant differences between treatment groups (CHX or MEL) vs controls (NW-Perio or HFD-Perio). Table 4 depicts the effect of the two adjunctive therapies on the levels of gingival tissue pro-inflammatory cytokines when compared with non-treated controls at week 29. The animals treated with melatonin resulted in statistically significant reductions in all measured cytokines (IL-1β, IL-6, MCP-1 and TNF-α), while in those treated with CHX only MCP-1 and TNF-α were significantly reduced. Table 5 reports the same comparisons on the levels of proinflammatory cytokines measured in plasma. Similar trends were found, but significantly greater reductions for IL-1β occurred in the melatonin-treated group when compared with the CHX-treated group. Table 6 reports the differences in other plasma biochemical biomarkers comparing both adjunctive treatments. A relevant increase in osteocalcin plasma levels occurred in both treatment groups, although differences were not statistically significant. Furthermore, both treatments reduced OPN, insulin and leptin plasma concentrations, being these reductions higher in the adjunctive melatonin group. In regards to the biomarkers associated with cardiovascular health, the administration of melatonin in HFD animals resulted in a significant (p < 0.05) reduction of PAI-1, E-Selectin and sI-CAM when compared with the non-treated group. However, these significant effects did not occur in the adjunctive CHX groups (NW-Perio-CHX and HFD-Perio-CHX). Similarly, a significant increase (p < 0.05)
in HDL-C levels and concomitant reductions in TG and FFA occurred in the groups treated with adjunctive melatonin, compared to the non-treated controls. In contrast, the groups treated with adjunctive CHX did not have a significant effect on these parameters.
| D ISCUSS I ON
The did not find a significant effect of using melatonin on periodontal outcome measurements, but they used melatonin as a preventive measure rather than as a therapeutic intervention.
This investigation has also reported a positive outcome on the biochemical biomarkers, both in plasma and in the gingival tissues, mainly when obese rats with periodontitis were treated with adjunctive melatonin. Significant reductions for IL-1β, IL-6, MCP-1 and TNF-α were found in the melatonin-treated group in the gingival samples and significant reductions in IL-1β in the plasma samples.
These findings are also in agreement with those reported by Renn et al. (2018) demonstrating a significant effect of melatonin in the reducing pro-inflammatory cytokines. Liu, Tipoe, & Fung (2014) also demonstrated that melatonin compensated the elevated proinflammatory cytokines levels encountered in hypoxic rats.
Previous experimental investigations from our research group have reported that obese rats with periodontitis demonstrated a significant increase in inflammatory biomarkers in plasma, gingival tissue or liver ) and significant reductions in plasma melatonin levels (Virto, Haugen, et al., 2018) in bone formation has been described in numerous studies, mainly since mice bone marrow cells are capable of synthesizing melatonin (Conti et al., 2000) . In mice, melatonin at low concentrations stimulates the proliferation of osteoblasts in vitro (Nakade, Koyama, Ariji, Yajima, & Kaku, 1999) and results in increased bone mineral density and trabecular structure in Koyama, Nakade, Takada, Kaku, and Lau (2002) .
In this investigation, we also have reported an effect of adjunctive melatonin application on the biomarkers associated with carbo- function has been demonstrated in humans (Tonetti et al., 2007) and similarly, PAI-1, a highly pro-thrombotic marker of fibrinolysis has shown significant reductions in the animals treated with melatonin (Akman, Fentoğlu, Yılmaz, & Arpak, 2012) . Among the possible regulatory pathways justifying these effects, melatonin modulates the TLR4/NF-kB system with a demonstrated protective role in the development of the atherosclerotic lesion (Hu et al., 2013) .
The results from this investigation, however, should not be directly translated to humans, since this experimental design has important shortcomings, mainly related to the methods used for disease induction and the administration of the treatments and dosages, as well as in the evaluation of clinical, bone repair and biochemical outcome measurements in this experimental model.
We have administered melatonin through the drinking water with the aim of studying the effect of this drug on multiple organs (Gulle et al., 2014) . In this study, we used 2.3 mg/kg of melatonin, although different doses have been reported in the literature for the treatment of periodontitis and even large doses have been reported in humans without significant severe adverse effects (Andersen et al., 2016) . Although we have used very delicate probing under high magnification, we understand that the translation of these measurements when using a periodontal probe designed for human tissues may not be fully appropriate. Similarly, the bone repair dynamics in the rat model differs substantially from humans.
| CON CLUS ION
In conclusion and within the clear limitations of this in vivo experimental study, the use of adjunctive systemic melatonin therapy has demonstrated a significant effect on periodontal tissues and metabolic response, mainly in the obese rats with periodontitis.
These results may suggest that this hormone has an important role on the co-morbidity effects demonstrated when these chronic inflammatory diseases co-exist. Even though the mechanisms associated with this effect are still not fully understood, it provides a clear hypothesis for the therapeutic use of melatonin as adjunct to the treatment of periodontitis, mainly when combined with obesity. This hypothesis should be tested in further experimental and clinical studies.
